Wang Jieting, Yu Luying, Zhou Ao, Liu Jie, Wang Kai, Luo Ying, Wang Fang
Key Laboratory of Nanomedical Technology (Education Department of Fujian Province), Nanomedical Technology Research Institute, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
Department of Biomedical Engineering, College of Engineering, Peking University, Beijing 100871, China.
Pharmaceutics. 2021 Sep 19;13(9):1520. doi: 10.3390/pharmaceutics13091520.
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality worldwide. Conventional therapies involving surgery or pharmacological strategies have shown limited therapeutic effects due to a lack of cardiac tissue repair. Gene therapy has opened an avenue for the treatment of cardiac diseases through manipulating the underlying gene mechanics. Several gene therapies for cardiac diseases have been assessed in clinical trials, while the clinical translation greatly depends on the delivery technologies. Non-viral vectors are attracting much attention due to their safety and facile production compared to viral vectors. In this review, we discuss the recent progress of non-viral gene therapies for the treatment of cardiovascular diseases, with a particular focus on myocardial infarction (MI). Through a summary of delivery strategies with which to target cardiac tissue and different cardiac cells for MI treatment, this review aims to inspire new insights into the design/exploitation of non-viral delivery systems for gene cargos to promote cardiac repair/regeneration.
心血管疾病（CVD）是全球发病和死亡的主要原因。由于缺乏心脏组织修复，涉及手术或药物策略的传统疗法显示出有限的治疗效果。基因治疗通过操纵潜在的基因机制为心脏病的治疗开辟了一条途径。几种用于心脏病的基因治疗已在临床试验中进行了评估，而临床转化很大程度上取决于递送技术。与病毒载体相比，非病毒载体因其安全性和易于生产而备受关注。在这篇综述中，我们讨论了用于治疗心血管疾病的非病毒基因治疗的最新进展，特别关注心肌梗死（MI）。通过总结针对心脏组织和不同心脏细胞进行心肌梗死治疗的递送策略，本综述旨在激发对用于基因载体的非病毒递送系统的设计/开发的新见解，以促进心脏修复/再生。
